Genferon light nasal spray 50000 IU / dose + 1mg / dose, No. 1

Prevention and treatment of influenza and ARVI in adults and children over 14 years old.

The drug is administered intranasal by aerosol administration of 1 dose (1 dose = 1 short press on the dispenser). At the first signs of illness, Genferon Light is administered intranasally for 5 days, one dose (one press on the dispenser) into each nasal passage 3 times a day (one dose is approximately 50,000 IU of interferon alfa, the daily dose should not exceed 500,000 IU). Upon contact with a patient with acute respiratory viral infections and / or hypothermia, the drug is administered according to the indicated scheme 2 times a day for 5-7 days. If necessary, prophylactic courses are repeated.

Instructions for using the spray:

1. Remove the protective cap.

2. Before using for the first time, press the dispenser several times until a thin stream appears.

3. When using, keep the bottle in an upright position.

4. Inject the drug by pressing the dispenser once into each nasal passage in turn.

5. After use, close the dispenser with the protective cap.

Individual use is recommended to avoid the spread of infection.

Dosed nasal spray in the form of a transparent, colorless or light yellow liquid, without visible mechanical impurities.

1 dose

interferon alpha-2b human recombinant * 50,000 IU

taurine 1 mg

* The composition of the substance 'Interferon alfa-2b human recombinant (rhIFN-? 2b), substance solution' includes recombinant human interferon alpha-2b (rhIFN-? 2b) and excipients: sodium chloride, sodium acetate trihydrate, glacial acetic acid, water d /and.

Excipients: disodium edetate dihydrate, glycerol, dextran 40,000, polysorbate 80, sodium chloride, potassium chloride, sodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, peppermint oil, methyl parahydroxybenzoate, water d / i - up to 0.1 ml.

• Hypersensitivity to interferon alfa-2b or other components of the drug;

• children under 14 years of age.

• With caution: patients suffering from nosebleeds.

pharmachologic effect

The Genferon Light preparation contains recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene has been genetically engineered. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by strengthening the cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8 + T-killers, NK-cells (natural killer cells), increased differentiation of B-lymphocytes and the production of antibodies by them,activation of the monocyte-macrophage system and phagocytosis, as well as an increase in the expression of type I major histocompatibility complex molecules, which increases the likelihood of recognition of infected cells by cells of the immune system. The activation of leukocytes contained in all layers of the mucous membrane under the influence of interferon ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by the reactions of the immune system, enhanced by the influence of interferon. Taurine contributes to the normalization of metabolic processes and tissue regeneration, has a membrane stabilizing and immunomodulatory effect. Being a strong antioxidant, taurine directly interacts with reactive oxygen species,excess accumulation of which contributes to the development of pathological processes. Taurine contributes to the preservation of the biological activity of interferon, enhancing the therapeutic effect of the drug.

Pharmacokinetics

With intranasal application, due to the high concentration in the focus of infection, a pronounced local antiviral and immunostimulating effect is achieved. Systemic absorption of the drug is insignificant - the low bioavailability of drugs when administered intranasally is associated with the functioning of a special family of proteins from 25 proteins that make up the nasal mucosa and control the transport of all molecular and cellular objects that penetrate through the mucosa. At the same time, a certain amount of the drug enters the systemic circulation, due to which a systemic immunomodulatory effect is achieved.

Side effect

Side effects when using the drug Genferon Light were not observed.

Application during pregnancy and lactation

Allowed to use during the entire period of pregnancy.

Application in children

Contraindicated in children under 14 years of age.

Overdose

No cases of overdose of Genferon Light have been reported.

Drug interactions

Not marked.